Bard antimicrobial Foley catheter marketing strategy includes risk-sharing offer.
This article was originally published in The Gray Sheet
BARD ANTIMICROBIAL FOLEY CATHETER MARKETING STRATEGY INCLUDES RISK SHARING offer with hospitals. The catheter was cleared by FDA in August 1994 with the claim that it can "reduce urinary tract infections by as much as 70%," Bard President and CEO William Longfield said at the recent Alex. Brown & Sons Health Care seminar. Bard says it began marketing efforts for the device within the last month.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.